Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high on Monday . The company traded as high as $68.19 and last traded at $64.50, with a volume of 392739 shares trading hands. The stock had previously closed at $64.96.
Gemini Therapeutics Stock Performance
The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of -62.65 and a beta of -0.12. The business’s 50-day moving average is $52.78 and its two-hundred day moving average is $46.58.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- Financial Services Stocks Investing
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Buy P&G Now, Before It Sets A New All-Time High
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Are the FAANG Stocks and Are They Good Investments?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
